Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580203 | 1.00 | KMT2A (0.55) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL5580201 | 1.00 | KMT2A (0.55) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL7276720 | 0.85 | KMT2A (0.46) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL25578544 | 0.85 | HDAC8 (0.48) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL29350881 | 0.85 | HDAC8 (0.58) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL44905 | 0.85 | HDAC8 (0.58) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL44904 | 0.85 | HDAC8 (0.58) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL1613174 | 0.85 | HDAC8 (0.58) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL28075883 | 0.84 | CYP3A4 (0.47) | KMT2AALOX15HSD17B10CYP3A4KDM4E | |
| SCHEMBL4140820 | 0.83 | KDM4E (0.66) | KMT2AALOX15HSD17B10CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931329-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| US-20240024268-A1 | Methods for Dopamine Modulation in Human Neurologic Diseases | SACKNER BERNSTEIN JONATHAN (US) | 2024-01-25 | — | — | US | claimed |
| US-20240016815-A1 | COMPOSITIONS AND METHODS FOR MODULATING CANCER IN NON-HUMAN MAMMALS | HOFFMAN TECHNOLOGIES LLC | 2024-01-18 | — | — | US | claimed |
| US-11806326-B2 | Methods for dopamine modulation in human neurologic diseases | SACKNER BERNSTEIN JONATHAN (US) | 2023-11-07 | — | — | US | claimed |
| US-11786496-B2 | Composition and methods for treating intestinal hyperpermeability | YAMO PHARMACEUTICALS LLC (US) | 2023-10-17 | — | — | US | claimed |
| US-20230141609-A1 | Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms | YAMO PHARMACEUTICALS LLC (US) | 2023-05-11 | — | — | US | claimed |
| US-20230040681-A1 | COMPOSITIONS AND METHODS FOR TREATING ANXIETY-RELATED DISORDERS | YAMO PHARMACEUTICALS LLC (US) | 2023-02-09 | — | — | US | claimed |
| US-11534420-B2 | Compositions and methods for treating cancer | TYME, INC. (US) | 2022-12-27 | — | — | US | claimed |
| CN-115515575-A | Tyrosine derivatives for the modulation of cancer | 迪美公司 | 2022-12-23 | — | — | CN | claimed |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-07-07 | — | — | US | claimed |
| WO-2015061256-A1 | HIGH-SPEED CENTRIFUGAL MIXING DEVICES AND METHODS OF USE | TYME, INC. (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015061328-A2 | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL HYPERPERMEABILITY | HOFFMAN STEVEN (US) | 2015-04-30 | — | — | WO | claimed |
| US-20150111937-A1 | Compositions and Methods for Treating Intestinal Hyperpermeability | YAMO PHARMACEUTICALS LLC | 2015-04-23 | — | — | US | claimed |
| US-20150111878-A1 | COMPOSITIONS AND METHODS FOR TREATING INTESTINAL HYPERPERMEABILITY | HOFFMAN STEVEN (US) | 2015-04-23 | — | — | US | claimed |
| US-20150110735-A1 | HIGH-SPEED CENTRIFUGAL MIXING DEVICES AND METHODS OF USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-04-23 | — | — | US | claimed |
| US-20150112116-A1 | TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-04-23 | — | — | US | claimed |
| EP-2804599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Tyme, Inc. (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013109610-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HOFFMAN STEVEN (US) | 2013-07-25 | — | — | WO | claimed |
| US-20130184214-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-18 | — | — | US | claimed |
| US-8481498-B1 | Pharmaceutical compositions and methods | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | TH, PAH, COMT | KMT2A 378/4885ALOX15 3582/4885HSD17B10 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.